Investor Centre

Founded in 1999 and listed on the Australian Securities Exchange in 2004, Cogstate (ASX.CGS) is a world-class neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare

Investor Webcast

FY20 Financial Results

Watch Cogstate CEO, Brad O’Connor present the FY20 Financial Results to analysts and media.

Watch the Webcast

Investor Relations

Corporate Governance

Cogstate's Board and management are committed to shareholder value

Board of Directors

Meet the Cogstate Board of Directors who bring a wealth of knowledge and experience to our business

Financial Reports

See our Annual and Half Year reports

Investor Presentations

View Cogstate's recent investor presentations

Financial Calendar

View our upcoming financial events

Shareholder Information

See information on Cogstate's shareholder services

Cogstate Highlights

Cogstate’s easy-to-use, computerised cognitive testing is based on science which has been widely accepted and validated both academically and commercially through hundreds of peer-reviewed publications

Cogstate solutions serve four distinct markets: Clinical Trials, Healthcare, Academic Research and Brain Injury

Cogstate has a history of strong financial performance with the Clinical Trials business enabling the company to self-fund R&D and commercialisation opportunities

Cogstate leverages its leading expertise in cognitive testing to penetrate growing markets in Healthcare and Brain Injury

ASX Announcements and Share Price

View Cogstate Limited’s share price and read our investor announcements on the Australian Securities Exchange.

Learn More

Receive Investor Updates

Please fill out the form to subscribe